AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27383196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD, 50% carbohydrates, 33% fat, including 57g/day of pistachios)
Number of subjects: 49
Study 27383196 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control diet (CD, 55% carbohydrates and 30% fat)
Number of subjects: 49
Study 27383196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD)
Number of subjects: 49
Study 26414670 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Medication Choice (DMC)
Number of subjects: 301
Study 26414670 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 301
Study 23344768 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed C sternotomy
Number of subjects: 35
Study 23344768 — intervention group
Group type: COMPARATOR
Intervention: Conventional sternotomy
Number of subjects: 35
Study 22238745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 38
Study 19920719 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 182
Study 19920719 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 182
Study 16953853 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EPIDURAL)
Number of subjects: 992
Study 16953853 — intervention group
Group type: COMPARATOR
Intervention: Other methods of pain relief including continuous midwifery support (CMS)
Number of subjects: 992
Study 15193681 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline quartile of echocardiographic LVM indexed to body surface area
Number of subjects: 3042
Study 15193681 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline echocardiographic LVM
Number of subjects: 3042
Study 15193681 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline electrocardiographic LVM
Number of subjects: 3042
Study 11319199 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise among normal volunteers
Number of subjects: 107
Study 11319199 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise among CAD patients
Number of subjects: 107
Study 9288516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia (CCP)
Number of subjects: 42
Study 9288516 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 42
Study 8314512 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial response after a meal
Number of subjects: 16
Study 8314512 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of mebeverine hydrochloride into the sigmoid colon
Number of subjects: 16
Study 2894246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipradilol (9 mg)
Number of subjects: 8
Study 29406814 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education (n=51)
Number of subjects: 129
Study 29406814 — intervention group
Group type: COMPARATOR
Intervention: Skill demonstration (control group; n=63)
Number of subjects: 129
Study 29406814 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 129
Study 29406814 — intervention group
Group type: COMPARATOR
Intervention: Skill demonstration
Number of subjects: 129
Study 27769675 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL liposomal bupivacaine (13.3 mg/mL)
Number of subjects: 95
Study 27769675 — intervention group
Group type: COMPARATOR
Intervention: 4 mL 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 95
Study 25439367 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (single budesonide‐formoterol inhaler as maintenance and reliever therapy)
Number of subjects: 303
Study 25439367 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (fixed‐dose regimen with salbutamol as reliever)
Number of subjects: 303
Study 25439367 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART
Number of subjects: 303
Study 22444829 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy (0.5 mg, administered monthly)
Number of subjects: 321
Study 22444829 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fluence (SF) verteporfin PDT plus ranibizumab
Number of subjects: 321
Study 22444829 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fluence (RF) verteporfin PDT plus ranibizumab
Number of subjects: 321
Study 22444829 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin SF
Number of subjects: 321
Study 22444829 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin RF
Number of subjects: 321
Study 22444829 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 321
Study 22444829 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (verteporfin SF or RF)
Number of subjects: 321
Study 20651204 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 300 mg I/mL, 50 mL contrast material followed by a 20-mL saline bolus at 3.0 mL/s
Number of subjects: 100
Study 20651204 — intervention group
Group type: COMPARATOR
Intervention: Group B: 300 mg I/mL, 100 mL contrast material at 3.0 mL/s
Number of subjects: 100
Study 18768944 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate ICD shock
Number of subjects: 811
Study 18768944 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate ICD shock
Number of subjects: 811
Study 18768944 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate ICD shock (survivors > 24 hours)
Number of subjects: 811
Study 16803614 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 20
Study 16803614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12749500 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 0
Study 12749500 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs) with community effect considered
Number of subjects: 0
Study 11040249 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet
Number of subjects: 65
Study 11040249 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet
Number of subjects: 65
Study 11040249 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-insensitive hypertensive patients
Number of subjects: 65
Study 11040249 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-sensitive hypertensive patients
Number of subjects: 65
Study 11040249 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 65
Study 11040249 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in FE(Li)
Number of subjects: 65
Study 8817986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic Ventricular Assist Device (VAD)
Number of subjects: 28
Study 8817986 — intervention group
Group type: COMPARATOR
Intervention: Venoarterial Bypass (VAB) with Percutaneous Cardiopulmonary Support (PCPS)
Number of subjects: 28
Study 1582239 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 49
Study 1582239 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 49
Study 2866960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg)
Number of subjects: 20
Study 2866960 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 20
Study 31238710 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 69
Study 31238710 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 69
Study 31238710 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 69
Study 29319646 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing (weekly phone calls for 12 weeks)
Number of subjects: 72
Study 29319646 — intervention group
Group type: COMPARATOR
Intervention: Control group (one follow-up phone call after 12 weeks)
Number of subjects: 72
Study 29319646 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing
Number of subjects: 72
Study 29319646 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 26832451 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation following ego depletion
Number of subjects: 183
Study 26832451 — intervention group
Group type: COMPARATOR
Intervention: Ego depletion without self-affirmation
Number of subjects: 183
Study 26832451 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation without ego depletion
Number of subjects: 183
Study 26832451 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-affirmation and no ego depletion)
Number of subjects: 183
Study 24954166 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV130 (1.5mg)
Number of subjects: 30
Study 24954166 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV130 (3mg)
Number of subjects: 30
Study 24954166 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV130 (4.5mg)
Number of subjects: 30
Study 24954166 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10mg)
Number of subjects: 30
Study 23129601 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 5 mg
Number of subjects: 556
Study 23129601 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 15 mg
Number of subjects: 556
Study 23129601 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 556
Study 23129601 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 556
Study 23129601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556
Study 20704110 — intervention group
Group type: COMPARATOR
Intervention: TGF‐β2 serum protein levels
Number of subjects: 63
Study 20704110 — intervention group
Group type: COMPARATOR
Intervention: TGF‐β3 serum protein levels
Number of subjects: 63
Study 20704110 — intervention group
Group type: COMPARATOR
Intervention: Kellgren‐Lawrence radiographic grading
Number of subjects: 63
Study 20704110 — intervention group
Group type: COMPARATOR
Intervention: WOMAC scale
Number of subjects: 63
Study 20704110 — intervention group
Group type: COMPARATOR
Intervention: TIMP‐1 levels
Number of subjects: 63
Study 20704110 — intervention group
Group type: COMPARATOR
Intervention: MMP‐2 and ‐9 activities
Number of subjects: 63
Study 18554189 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE BOND (SB)
Number of subjects: 20
Study 18554189 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide cement (CH)
Number of subjects: 20
Study 18554189 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20
Study 16236035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 23
Study 16236035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12440353 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (Xenical)
Number of subjects: 3277
Study 12440353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3277
Study 10088139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 7.5 mg/day with TSD
Number of subjects: 40
Study 10088139 — intervention group
Group type: COMPARATOR
Intervention: Placebo with TSD
Number of subjects: 40
Study 10088139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol with TSD
Number of subjects: 40
Study 7582879 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives of probands with OCD and MDD
Number of subjects: 0
Study 7582879 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives of probands with OCD and GAD
Number of subjects: 0
Study 7582879 — intervention group
Group type: COMPARATOR
Intervention: Relatives of probands with OCD
Number of subjects: 0
Study 2075854 — intervention group
Group type: EXPERIMENTAL
Intervention: Short form of the Alcohol Expectancy Questionnaire‐Adolescent Form (27 items)
Number of subjects: 377
Study 2075854 — intervention group
Group type: COMPARATOR
Intervention: Long form of the Alcohol Expectancy Questionnaire‐Adolescent Form (7 scales)
Number of subjects: 377
Study 7025683 — intervention group
Group type: EXPERIMENTAL
Intervention: CCVPP (cyclophosphamide‐vinblastine‐procarbazine‐prednisone with CCNU)
Number of subjects: 152
Study 7025683 — intervention group
Group type: COMPARATOR
Intervention: CVPP (cyclophosphamide‐vinblastine‐procarbazine‐prednisone without CCNU)
Number of subjects: 152
Study 7025683 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multidrug chemotherapy
Number of subjects: 152
Study 31819377 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 25‐G pars plana vitrectomy (PPV) with intravitreal dexamethasone implant (DXI)
Number of subjects: 40
Study 31819377 — intervention group
Group type: COMPARATOR
Intervention: Standard 25‐G PPV with ERM peeling only (control group)
Number of subjects: 40
Study 29097876 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination after screening
Number of subjects: 1215
Study 29097876 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly defined)
Number of subjects: 1215
Study 26493248 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 10026
Study 26493248 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 10026
Study 24066730 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality HTN-CVD care package delivered through private health facilities
Number of subjects: 912
Study 24066730 — intervention group
Group type: COMPARATOR
Intervention: Current practice at private health facilities
Number of subjects: 912
Study 21842352 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary research interventions related to functional competence and health promotion.
Number of subjects: 0
Study 21842352 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled intervention
Number of subjects: 0
Study 21842352 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal cohort follow‐up study
Number of subjects: 0
Study 21842352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐sectional comparative studies
Number of subjects: 0
Study 21842352 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective intervention studies
Number of subjects: 0
Study 19705400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound exposure at any time during fetal life
Number of subjects: 4458
Study 19705400 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound exposure in the second trimester
Number of subjects: 4458
Study 17234519 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg
Number of subjects: 48
Study 17234519 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 50 mg
Number of subjects: 48
Study 17234519 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Number of subjects: 48
Study 15200998 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (C), 192 patients, three 3-weekly cycles of cisplatin/vindesine, mitomycin/ifosfamide/cisplatin, mitomycin/vinblastine/cisplatin or vinorelbine/cisplatin.
Number of subjects: 381
Study 15200998 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (NoC), 189 patients.
Number of subjects: 381
Study 11800186 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stimulus engagement (SSE) preference assessment
Number of subjects: 4
Study 9555596 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (RIS) 6.9 mg
Number of subjects: 123
Study 9555596 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol and Amitriptyline (HAL/AMI) 9 mg and 180 mg respectively
Number of subjects: 123
Study 9555596 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (RIS)
Number of subjects: 123
Study 9555596 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol and Amitriptyline (HAL/AMI)
Number of subjects: 123
Study 8041438 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography (MRA)
Number of subjects: 54
Study 8041438 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral four-vessel angiography (conventional angiography)
Number of subjects: 54
Study 2839442 — intervention group
Group type: COMPARATOR
Intervention: Conventional daily radiation (5 x W) - 5 daily fractions of 2 Gy each to a total dose of 60 Gy in 6 weeks, protecting the spinal cord at 45 Gy.
Number of subjects: 150
Study 2839442 — intervention group
Group type: EXPERIMENTAL
Intervention: Once‐a‐week radiation (1 x W) - one weekly fraction of 5 Gy each to a total tumor dose of 60 Gy in 12 weeks, protecting the spinal cord at 30 Gy.
Number of subjects: 150
Study 31763943 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B 25 mg IV-RLP
Number of subjects: 9
Study 31763943 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B 50 mg IV-RLP
Number of subjects: 9
Study 31763943 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B 300 mg IV-RLP
Number of subjects: 9
Study 28600107 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone
Number of subjects: 969
Study 28600107 — intervention group
Group type: COMPARATOR
Intervention: Mail
Number of subjects: 969
Study 28600107 — intervention group
Group type: COMPARATOR
Intervention: E-Mail
Number of subjects: 969
Study 25403578 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 (oxaliplatin 85 mg/m²)
Number of subjects: 284
Study 25403578 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX7 (oxaliplatin 130 mg/m²) followed by FOLFIRI (irinotecan 180 mg/m²)
Number of subjects: 284
Study 23598459 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic adjustment according to the AAD (algorithm de ajuste de diurético)
Number of subjects: 34
Study 23598459 — intervention group
Group type: COMPARATOR
Intervention: Conventional adjustment (control group)
Number of subjects: 34
Study 21443379 — intervention group
Group type: EXPERIMENTAL
Intervention: Novices receiving additional text explaining the animations
Number of subjects: 104
Study 21443379 — intervention group
Group type: COMPARATOR
Intervention: Novices without additional text explaining the animations
Number of subjects: 104
Study 21443379 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts receiving additional text explaining the animations
Number of subjects: 104
Study 21443379 — intervention group
Group type: COMPARATOR
Intervention: Experts without additional text explaining the animations
Number of subjects: 104
Study 19514695 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipneumococcal fluoroquinolone
Number of subjects: 0
Study 19514695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose beta-lactam/beta-lactamase inhibitor or second-/third-generation cephalosporin with azithromycin
Number of subjects: 0
Study 19514695 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics for hospitalized patients
Number of subjects: 0
Study 16675478 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil-tegafur (400 mg/m2 tegafur per day) for one year
Number of subjects: 274
Study 16675478 — intervention group
Group type: COMPARATOR
Intervention: No treatment (surgery-alone group)
Number of subjects: 274
Study 14722640 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG‐PDR(0.5) with dosage 0.5 mg/kg
Number of subjects: 16
Study 14722640 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG‐PDR(0.25) with dosage 0.25 mg/kg
Number of subjects: 16
Study 11803864 — intervention group
Group type: EXPERIMENTAL
Intervention: Melbrosia treatment group
Number of subjects: 66
Study 11803864 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 9557910 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg(‐1) ephedrine intramuscularly
Number of subjects: 90
Study 9557910 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg.kg(‐1) propofol intravenously
Number of subjects: 90
Study 9557910 — intervention group
Group type: COMPARATOR
Intervention: 0.1 ml.kg(‐1) normal saline intravenously
Number of subjects: 90
Study 9557910 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine
Number of subjects: 90
Study 9557910 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol
Number of subjects: 90
Study 7849542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride therapy (mean, 23 mg elemental F daily for approximately 18 months)
Number of subjects: 25
Study 7849542 — intervention group
Group type: COMPARATOR
Intervention: Control group (38 osteoporotic females not receiving fluoride therapy)
Number of subjects: 25
Study 7849542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride therapy
Number of subjects: 25
Study 7849542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 3170393 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin 15.0 mg/kg administered in a single daily dose
Number of subjects: 45
Study 3170393 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin 11.0 mg/kg administered in a single daily dose
Number of subjects: 45
Study 3170393 — intervention group
Group type: COMPARATOR
Intervention: amikacin 7.5 mg/kg administered twice daily
Number of subjects: 45
Study 31804853 — intervention group
Group type: EXPERIMENTAL
Intervention: Google Cardboard headset (low-cost VR device)
Number of subjects: 48
Study 29459408 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of TTR results
Number of subjects: 481
Study 29459408 — intervention group
Group type: COMPARATOR
Intervention: No provision of TTR results
Number of subjects: 481
Study 28228151 — intervention group
Group type: EXPERIMENTAL
Intervention: Activate intervention (4 nurse-led consultations over 3 months, integrating 17 behaviour change techniques)
Number of subjects: 279
Study 28228151 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 279
Study 26251078 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-O blood groups
Number of subjects: 1835
Study 24146467 — intervention group
Group type: EXPERIMENTAL
Intervention: Saponin SC-2 from Solanum chrysotrichum
Number of subjects: 0
Study 24146467 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 0
Study 20864423 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral 5% glucose infusion (25 ml h(‐1) via jejunostomy tube initiated 6h after surgery)
Number of subjects: 23
Study 20864423 — intervention group
Group type: COMPARATOR
Intervention: Control group (peripheral parenteral nutrition for seven post-operation days)
Number of subjects: 23
Study 20864423 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral 5% glucose infusion
Number of subjects: 23
Study 20864423 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23